Tisch Cancer Institute at Mount Sinai

Videos
20:01

Tisch Cancer Institute at Mount Sinai

Summary of Efficacy and Safety Data of Venetoclax in 1L AML + ASH 2024 Venetoclax Updates

FEATURING Jonathan Feld
  • 28 views
  • March 27, 2025
05:46

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Ruxolitinib for JAK Inhibitor–Naïve Patients With MF

FEATURING John Mascarenhas
  • 126 views
  • December 27, 2024
11:06

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available Therapy in JAK Inhibitor R/R MF

FEATURING John Mascarenhas
  • 54 views
  • December 27, 2024
15:23

Tisch Cancer Institute at Mount Sinai

Non Immune-Based Approaches for Advanced Myeloma

FEATURING Gurbakhash Kaur
  • 100 views
  • November 21, 2024
06:30

Tisch Cancer Institute at Mount Sinai

ASTRO 2023 Insights: "Treatment Landscape for mCRPC - Lu-177-PSMA, Radium 223, and Future of RLT"

FEATURING William Oh
  • 203 views
  • November 3, 2023
10:51

SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: Myeloproliferative Neoplasms

FEATURING John Mascarenhas
  • 67 views
  • October 19, 2023
  • 1
17:34

SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Novel Non-JAK Inhibitor Therapies for Myelofibrosis

FEATURING John Mascarenhas
  • 233 views
  • October 10, 2023
01:07

WCLC 2022 Conference Coverage

Lecture Summary - WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes With PD-L1 Blockade to Reverse Type-2 Mediated Immunosuppression

FEATURING Thomas Marron
  • 14 views
  • September 6, 2022
11:14

WCLC 2022 Conference Coverage

WCLC 2022 on Cancer and Atopy: Parallel Drivers? IL-4 Blockade Synergizes With PD-L1 Blockade to Reverse Type-2 Mediated Immunosuppression

FEATURING Thomas Marron
  • 52 views
  • September 6, 2022
09:41

i3 Health

Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis

FEATURING John Mascarenhas
  • 98 views
  • July 15, 2022
05:07

Icahn School of Medicine at Mount Sinai

TKI in the Management of Advanced HCC

FEATURING Augusto Villanueva
  • 237 views
  • July 7, 2022
11:42

Icahn School of Medicine at Mount Sinai

Symptom Assessments in Myelofibrosis and How to Examine the Spleen

FEATURING Marina Kremyanskaya
  • 75 views
  • June 2, 2022
04:20

Oncology Data Advisor

The Roles of Etiology and Biopsy in Hepatocellular Carcinoma

FEATURING Augusto Villanueva
  • 35 views
  • April 27, 2022
20:43

Tisch Cancer Institute at Mount Sinai

PD-L1 Expression: Practical Implications in Advanced Stage NSCLC

FEATURING Fred Hirsch
  • 198 views
  • March 16, 2022
  • 1
07:13

ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myelofibrosis and Severe Thrombocytopenia

FEATURING John Mascarenhas
  • 166 views
  • March 2, 2022
06:20

ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolitinib in Patients With Myelofibrosis and Moderate-to-Severe Thrombocytopenia

FEATURING John Mascarenhas
  • 117 views
  • March 2, 2022
05:04

ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

FEATURING Augusto Villanueva
  • 173 views
  • January 26, 2022
15:25

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST Trial: Pelabresib Monotherapy for Myelofibrosis

FEATURING Marina Kremyanskaya
  • 92 views
  • December 20, 2021
07:56

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with MF

FEATURING John Mascarenhas
  • 57 views
  • December 17, 2021
05:15

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

FEATURING John Mascarenhas
  • 622 views
  • December 15, 2021
  • 2
21:07

2021 International Congress on Myeloproliferative Neoplasms

Persistent Leukocytosis and PV Progression: Prognostic and Therapeutic Implications

FEATURING John Mascarenhas
  • 18 views
  • December 15, 2021
01:47

2021 ASCO Virtual Direct™ Highlights

2021 ASCO Summary on COVID-19 & Cancer

FEATURING Deborah Doroshow
  • 10 views
  • August 19, 2021
08:32

Tisch Cancer Institute at Mount Sinai

2020 NSCLC Update: Does PD-L1 Predict Pembrolizumab Response in Patients With Both Squamous and Nonsquamous NSCLC?

FEATURING Deborah Doroshow
  • 166 views
  • September 16, 2020
  • 1
06:49

Tisch Cancer Institute at Mount Sinai

Can Pacritinib Be Used to Treat Cytokine Storm in Patients With COVID-19? What Was the Primary End Point of the Trial & Which Patients Are Eligible for the Treatment?

FEATURING John Mascarenhas
  • 3,142 views
  • May 25, 2020
  • 10
28:34

Tisch Cancer Institute at Mount Sinai

Managing Hepatocellular Carcinoma: Early Detection and Diagnosis, Staging and Treatment Options - Efficacy of Checkpoint Inhibitors and Combination Systemic Therapy?

FEATURING Augusto Villanueva
  • 364 views
  • August 27, 2019
  • 2
07:57

Tisch Cancer Institute at Mount Sinai

Epidemiology of Hepatocellular Carcinoma: Disease Burden and Trends

FEATURING Augusto Villanueva
  • 86 views
  • August 27, 2019
11:35

Tisch Cancer Institute at Mount Sinai

Clinical Challenges in Management of Hepatocellular Carcinoma: Liquid Biopsy and Biomarker Development

FEATURING Augusto Villanueva
  • 55 views
  • August 27, 2019
24:22

Tisch Cancer Institute at Mount Sinai

Update on Clinical Trials in Myeloproliferative Neoplasms

FEATURING John Mascarenhas
  • 400 views
  • November 28, 2017
  • 2